News Headlines

  1. Genstar Capital To Acquire CRF Health From Vitruvian Partners And Combine With Bracket

    Genstar Capital, a leading investor in healthcare technology and services companies, is pleased to announce the acquisition of CRF Health, a global provider of eCOA and eConsent solutions for the life sciences industry.

  2. Rising Protocol Complexity Is Hindering Performance While Driving Up Cost Of Clinical Trials, According To The Tufts Center For The Study Of Drug Development

    Rising protocol complexity is hindering clinical trial performance and efficiency, and helping to drive up the cost of developing new drugs, according to a recently completed analysis by the Tufts Center for the Study of Drug Development.

  3. FDA Approves The First Drug With An Indication For Treatment Of Smallpox

    The U.S. Food and Drug Administration recently approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox.

  4. Zogenix Announces Positive Top-Line Results From Second Pivotal Phase 3 Clinical Trial Of ZX008 In Dravet Syndrome

    Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome.

  5. Aeromics Initiates Phase 1 Clinical Trial Of CNS Edema Inhibitor AER-271 In Healthy Human Volunteers

    Aeromics, Inc. ("Aeromics" or "the Company"), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by disabling and life-threatening severe ischemic stroke, announced today the initiation of a Phase 1 clinical trial in healthy volunteers of its first-in-class drug candidate, AER-271.

  6. Bavarian Nordic Announces Initiation Of Phase 2 Trial Evaluating The Combination Therapy Of CV301 And Nivolumab In Metastatic Colorectal Cancer

    Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301, and Bristol Myers Squibb's checkpoint inhibitor, nivolumab (OPDIVO®), for the treatment of patients with resectable hepatic-limited metastatic colorectal cancer (mCRC).

  7. Cara Therapeutics Announces Dosing Of Patients In Phase 2 Trial Of Oral KORSUVA™ (CR845/difelikefalin) For Pruritus In Stage III-V Chronic Kidney Disease (CKD) Patients

    Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced that the first patients have been dosed in a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of pruritus in stage III-V (moderate-to-severe) CKD patients.

  8. VIVUS Announces Positive Results From A Phase 1 Clinical Trial Of VI-0106

    VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, today announced positive preliminary results from a Phase 1 clinical study evaluating the pharmacokinetic (PK) profile of its VI-0106 in healthy volunteers.

  9. Publication By VBL Therapeutics Highlights MOSPD2 As A Potential New Target For Breast Cancer Therapy

    VBL Therapeutics (NASDAQ:VBLT) today announced the publication of data on the potential role of MOSPD2 in metastatic breast cancer in the International Journal of Cancer.

  10. MMS Supported Clinical Data Aspects In Gemphire Therapeutics Meeting Its Primary Endpoint In Gemcabene Study

    MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced recently its integrated support for Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and nonalcoholic steatohepatitis (NASH).